Seattle Genetics

Mail: 21823 30th Drive Southeast, Bothell, WA 98021

Public
Healthcare & Pharmaceuticals - Biotechnology
around $100 - 500M
around 1K - 5K
(425) 527-4000
(425) 527-4001
hr@seattlegenetics.com


Seattle Genetics, Inc. (Seattle Genetics), is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protea... (Source: SEC reports)


Competitor - 1/8
Which company is more competitive with Seattle Genetics?




55 Contacts at this company
Scott Schliebner
Clinical Operations Manager
Todd Simpson
Chief Financial Officer
Tim Carroll
Chief Information Officer
Timothy Ayers
Associate General Counsel, Executive Director, Com
Peter Senter
VP, Distinguished Research Fellow
Fan (Allie) Wu
Sr. Statistician
Philip Tsai
Vice President, Process Sciences
Alyson Smith
Principal Scientist
Fu Li
Principal Scientist, Immunology

No company news available.
Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.